March 3, 2020 09:24 AM ESTUpdated 04:42 PM

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again

Natalie Grover

Reporter

Atlas Venture-backed Unum, which once harbored ambitions to rival the two CAR-T therapies Kymriah and Yescarta, is paying the price for a laundry list of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again

Natalie Grover

Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Fail­ure-prone Unum cuts jobs, los­es sci­en­tif­ic chief, and changes fo­cus yet again

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again

Why the Supreme Court's overrule of Chevron has major implications for the FDA

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs